FDA cites shortcomings with Genzyme study of leukemia drug for frail, elderly patients

FDA: problems with Genzyme study of leukemia drug

WASHINGTON — Federal regulators on Friday questioned whether Genzyme’s leukemia drug Clolar should be approved for older patients based on limited studies conducted by the biotech drugmaker.